Emerald Health Therapeutics Appoints Robert C. Hill, CPA, CA as Chief Financial Officer and Promotes Cheryl Evans … – GlobeNewswire (press release)

This Article Was Originally From This Site

VICTORIA, B.C., Nov. 20, 2017 (GLOBE NEWSWIRE) — Emerald Health Therapeutics Inc. (TSXV:EMH) (OTCQX:EMHTF) (“Emerald”) today announced the appointment of Robert C. Hill, CPA, CA, as the Company’s Chief Financial Officer and the promotion of Cheryl L. Evans, CPA, CA, to Vice President Finance. Together Mr. Hill and Ms. Evans will be responsible for leading Emerald’s financial operations and organizational functions to facilitate the significant anticipated expansion of the Company’s business with the expected legalization of adult use cannabis in Canada by July 2018. Sandy Pratt, CPA, CA, has resigned as Chief Financial Officer to pursue other opportunities. 
“We welcome Rob to Emerald’s executive team. His experience in strategic planning, financial and operational management, and building collaborative, high-performing organizations will help us further advance our mission to be a leader in the global cannabis industry,” said Chris Wagner, Chief Executive Officer of Emerald.“Cheryl has been impactful since starting as Emerald’s controller earlier this year. We will benefit from her expertise in internal and external financial reporting, budgeting, controls and software systems to support our rapid growth. We also sincerely thank Sandy Pratt for her dedication and valuable contributions to Emerald’s growth over the past two years.”Mr. Hill brings over 20 years of accounting, finance, and senior leadership experience to Emerald as a seasoned manager of private and publicly traded technology and financial services businesses in Canada, USA, and Asia. Prior to joining Emerald, Mr. Hill was the Chief Financial Officer of Tokyo-based Minkabu, a technology company advancing sophisticated stock market intelligence and financial data solutions. Before that, he held financial leadership positions at Haywood Securities in Vancouver, and Vignette Corp. and Trilogy Software in Austin, Texas.Mr. Hill earned a Bachelor of Science from the University of British Columbia and his certification from the Chartered Professional Accountants of British Columbia, Canada while articling with KPMG LLP.Mr. Hill has been granted an option to acquire up to 250,000 common shares vesting over three years.Ms. Evans has almost 20 years of management experience in the accounting, finance and treasury functions of publicly listed and highly regulated private companies. Prior to Emerald, she held various roles including Director, Regulatory Compliance and Director, Finance at AscendantFX Capital Inc, an international foreign currency payments provider, and VP, Financial Operations at Partners Real Estate Investment Trust.Ms. Evans achieved her Bachelor of Commerce in international business, with distinction, from the University of Victoria. She articled at Grant Thornton LLP for her CPA, CA designation, and subsequently worked with publicly listed companies at KPMG LLP. Join us on our journey of making lives better through cannabis science.About Emerald Health Therapeutics Inc.Emerald Health Therapeutics, Inc. (TSXV:EMH) (OTCQX:EMHTF) operates through Emerald Health Botanicals Inc. (“Botanicals”), a wholly owned subsidiary and Licensed Producer under Canada’s Access to Cannabis for Medical Purposes Regulations. Botanicals is authorized to produce and sell dried medical cannabis flower and medical cannabis oil. It currently operates an indoor facility in Victoria, BC, and is building a 150,000 s.f. hybrid greenhouse on 32 acres in Metro Vancouver, with the potential to expand this facility to 1 million s.f. to address the needs of the legal Canadian recreational cannabis market. Botanicals has also entered into a partnership with Village Farms to convert an existing 1.1 million s.f. greenhouse in Delta, BC from growing tomatoes to growing cannabis. Emerald’s team is highly experienced in life sciences, product development and large-scale agribusiness. Emerald and Botanicals are part of the Emerald Health group, which is broadly focused on developing pharmaceutical, botanical and nutraceutical products designed to provide wellness and medical benefits through interacting with the human body’s endocannabinoid system.For investor and media contacts:
invest@emeraldhealth.ca
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Cautionary Statements Regarding Forward Looking InformationCertain statements in this press release constitute forward-looking statements, within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, are “forward-looking statements”.We caution you that such “forward-looking statements” involve known and unknown risks and uncertainties that could cause actual and future events to differ materially from those anticipated in such statements.Forward-looking statements include, but are not limited to, statements with respect to expansion of Emerald’s business; creation of strategic development opportunities;  commercial operations; construction or conversion of production facilities; international opportunities for the Company; the Company becoming a leading Canadian supplier of cannabis products; expected timing of any of the above matters; and other information that is based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management.Emerald Health Therapeutics Inc. does not intend, and does not assume any obligation, to update these forward-looking statements except as required by law. These forward-looking statements involve risks and uncertainties relating to, among other things, failure to obtain regulatory approval for closing of the proposed transaction or to meet the conditions set out in the Agreement; failure of the federal government to approve legislation legalizing sales of non-therapeutic adult-use cannabis; failure to obtain Health Canada and other regulatory approvals; failure to obtain necessary financing; results of production and sale activities; the Company’s historical experience with medical marijuana operations; results of scientific research; uninsured risks; regulatory changes; difficulties in construction or in obtaining qualified contractors to complete construction or conversion of facilities; availability of production facilities; timeliness of government approvals and the granting of permits and licenses; changes in prices and costs; actual operating and financial performance of facilities; equipment and processes relative to specifications and expectations; as well as the other risk factors set out in the Company’s annual information form and other filings with the applicable Canadian securities regulators, which may be viewed at www.sedar.com. Actual results may differ materially from those expressed or implied by such forward-looking statements.

This Article Was Originally From *This Site*